Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: A pilot study

Journal of Nuclear Medicine

Volumn 55, Issue 8, 2014, Pages 1248-1252

  Wild, Damian ^a,b   Fani, Melpomeni ^a,b   Fischer, Richard ^a,c   Pozzo, Luigi Del ^a   Kaul, Felix ^a,b   Krebs, Simone ^a   Rivier, Jean E F ^d   Reubi, Jean Claude ^e   Maecke, Helmut R ^a,f   Weber, Wolfgang A ^a,f,g  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Onkologie Dreiländereck   (Germany)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e UNIVERSITY OF BERN   (Switzerland)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antagonists; Neuroendocrine tumors; Somatostatin receptor targeting

Indexed keywords

DIAGNOSTIC AGENT; LUTETIUM TETRAXETAN JR11 LU 177; LUTETIUM TETRAXETAN OCTREOTIDE[3 TYROSINE] LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; LUTETIUM; OCTREOTIDE; OLIGOPEPTIDE; ORGANOMETALLIC COMPOUND; RADIOISOTOPE; SOMATOSTATIN RECEPTOR;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; DOSIMETRY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG UPTAKE; FEASIBILITY STUDY; FEMALE; HUMAN; ILEUM TUMOR; ISOTOPE LABELING; LUNG TUMOR; MALE; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; PILOT STUDY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTOPENIA; ADULT; AGONISTS; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; NEUROENDOCRINE TUMORS; RADIOGRAPHY; RADIOMETRY; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; AMINO ACID SEQUENCE; FEASIBILITY STUDIES; FEMALE; HUMANS; LUTETIUM; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; OLIGOPEPTIDES; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; RADIOISOTOPES; RADIOMETRY; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84905482193     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.138834     Document Type: Article

References (10)

1. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5:382-393.
2. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441.
3. Cescato R, Waser B, Fani M, Reubi JC. Evaluation of 177Lu- DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52:1886-1890.
4. Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52:1412-1417.
5. Fani M, Braun F, Waser B, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53:1481-1489.
6. Wierts R, de Pont CD, Brans B, Mottaghy FM, Kemerink GJ. Dosimetry in molecular nuclear therapy. Methods. 2011;55:196-202.
7. Schweizer B, Schaefer A, Donsch P, et al. Evaluation of voxel-based dosimetry for targeted radionuclide therapies in phantom studies [abstract]. Eur J Nucl Med Mol Imaging. 2009;36(suppl 2):S428.
8. Wild D, Bomanji JB, Benkert P, et al. Comparison of 68Ga- DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364-372.
9. Bubeck B. Renal clearance determination with one blood sample: improved accuracy and universal applicability by a new calculation principle. Semin Nucl Med. 1993;23:73-86.
10. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.